COMMUNIQUÉS West-GlobeNewswire

TerrAscend to Host Second Quarter 2026 Earnings Conference Call
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the “Company”) (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
16/07/2026
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a [...]
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
16/07/2026
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells [...]
Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members
16/07/2026
RALEIGH, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. , a specialty pharmaceutical company advancing the science of testosterone therapy and hormone health, today welcomed Defense Secretary Pete [...]
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
16/07/2026
Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the [...]
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
16/07/2026
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the [...]
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
16/07/2026
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX ® -C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary [...]
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
16/07/2026
BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Phase II [...]
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
16/07/2026
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both [...]
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
16/07/2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, [...]
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
16/07/2026
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety [...]
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
16/07/2026
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the [...]
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET [...]
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026
The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE [...]
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
16/07/2026
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end viral vector [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/07/2026
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07/2026
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine [...]

Pages